Literature DB >> 7798976

Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET.

P Balestri1, G Lucignani, A Fois, L Magliani, L Calistri, C Grana, R M Di Bartolo, D Perani, F Fazio.   

Abstract

Cerebral PET with [18F]-2-fluoro-2-deoxy-D-glucose has been performed in four patients with neurofibromatosis type 1 (NF1) to assess the relation between cerebral metabolic activity, MRI, and the presence of neurological symptoms, including seizures, as well as mental and language retardation. Widespread hypometabolism occurred in three of the patients. The lesions on MRI, which were localised in the subcortical white matter and grey structures, had normal rates of glucose metabolism. This finding suggests that the abnormalities seen on MRI are not due to defective blood supply, localised oedema, or grey matter heterotopic foci as previously hypothesised. The presence of the hypometabolic areas seems to be inconsistently related to the occurrence of seizures and is not proportional to the degree of mental impairment. This study provides evidence of a widespread cerebral hypometabolism that is not related to the presence of MRI abnormalities; conversely normal metabolism was present in the areas with an abnormal MRI signal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7798976      PMCID: PMC1073228          DOI: 10.1136/jnnp.57.12.1479

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Authors:  L Sokoloff; M Reivich; C Kennedy; M H Des Rosiers; C S Patlak; K D Pettigrew; O Sakurada; M Shinohara
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

2.  The central nervous system pathology in multiple neurofibromatosis.

Authors:  J Pearce
Journal:  Neurology       Date:  1967-07       Impact factor: 9.910

3.  Neurological aspects of neurofibromatosis.

Authors:  A E Rubenstein; C Mytilineoau; M D Yahr; R P Revoltella
Journal:  Adv Neurol       Date:  1981

4.  Patterns of seizures observed in association with neurofibromatosis 1.

Authors:  B R Korf; E Carrazana; G L Holmes
Journal:  Epilepsia       Date:  1993 Jul-Aug       Impact factor: 5.864

5.  MR imaging and positron emission tomography of cortical heterotopia.

Authors:  D Bairamian; G Di Chiro; W H Theodore; M D Holmes; R H Dorwart; S M Larson
Journal:  J Comput Assist Tomogr       Date:  1985 Nov-Dec       Impact factor: 1.826

6.  Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose.

Authors:  M Reivich; A Alavi; A Wolf; J Fowler; J Russell; C Arnett; R R MacGregor; C Y Shiue; H Atkins; A Anand
Journal:  J Cereb Blood Flow Metab       Date:  1985-06       Impact factor: 6.200

7.  Positron emission tomography study of human brain functional development.

Authors:  H T Chugani; M E Phelps; J C Mazziotta
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

8.  Effect of phenytoin on human cerebral glucose metabolism.

Authors:  W H Theodore; D Bairamian; M E Newmark; G DiChiro; R J Porter; S Larson; D Fishbein
Journal:  J Cereb Blood Flow Metab       Date:  1986-06       Impact factor: 6.200

9.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution.

Authors:  K Hamacher; H H Coenen; G Stöcklin
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

10.  MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment.

Authors:  R E Ferner; R Chaudhuri; J Bingham; T Cox; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

View more
  6 in total

1.  Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.

Authors:  Mahendranath Moharir; Kevin London; Robert Howman-Giles; Kathryn North
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-24       Impact factor: 9.236

2.  Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.

Authors:  Ivayla Apostolova; Dagmara Niedzielska; Thorsten Derlin; Eva J Koziolek; Holger Amthauer; Benedikt Salmen; Jens Pahnke; Winfried Brenner; Victor F Mautner; Ralph Buchert
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-18       Impact factor: 6.200

3.  Reduced cerebral arterial spin-labeled perfusion in children with neurofibromatosis type 1.

Authors:  K W Yeom; R M Lober; P D Barnes; C J Campen
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

4.  Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.

Authors:  Manuel Schütze; Danielle de Souza Costa; Jonas Jardim de Paula; Leandro Fernandes Malloy-Diniz; Carlos Malamut; Marcelo Mamede; Débora Marques de Miranda; Michael Brammer; Marco Aurélio Romano-Silva
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

5.  Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.

Authors:  Diogo Lisbôa Basto; Gustavo de Souza Vieira; Raquel M Andrade-Losso; Paula Nascimento Almeida; Vincent M Riccardi; Rafaela Elvira Rozza-de-Menezes; Karin Soares Cunha
Journal:  Orphanet J Rare Dis       Date:  2022-09-05       Impact factor: 4.303

6.  Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).

Authors:  Stavros Stivaros; Shruti Garg; Jonathan Green; Maria Tziraki; Ying Cai; Owen Thomas; Joseph Mellor; Andrew A Morris; Carly Jim; Karolina Szumanska-Ryt; Laura M Parkes; Hamied A Haroon; Daniela Montaldi; Nicholas Webb; John Keane; Francisco X Castellanos; Alcino J Silva; Sue Huson; Stephen Williams; D Gareth Evans; Richard Emsley
Journal:  Mol Autism       Date:  2018-02-22       Impact factor: 7.509

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.